Total Payments
$654,301
2024 Payments
$34,126
Companies
43
Transactions
788
Medicare Patients
2,151
Medicare Billing
$358,887
Payment Breakdown by Category
Other$237,761 (36.3%)
Research$199,304 (30.5%)
Consulting$145,070 (22.2%)
Travel$52,962 (8.1%)
Food & Beverage$18,705 (2.9%)
Education$498.50 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $199,304 | 67 | 30.5% |
| Consulting Fee | $145,070 | 46 | 22.2% |
| Honoraria | $131,925 | 31 | 20.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $105,836 | 43 | 16.2% |
| Travel and Lodging | $52,962 | 124 | 8.1% |
| Food and Beverage | $18,705 | 471 | 2.9% |
| Education | $498.50 | 6 | 0.1% |
Payments by Type
General
$454,997
721 transactions
Research
$199,304
67 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sun Pharmaceutical Industries Inc. | $155,961 | 110 | $0 (2023) |
| Celgene Corporation | $142,772 | 24 | $0 (2020) |
| Genentech USA, Inc. | $54,793 | 61 | $0 (2023) |
| Eli Lilly and Company | $42,364 | 19 | $0 (2024) |
| Incyte Corporation | $38,715 | 39 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $35,410 | 73 | $0 (2024) |
| DERMIRA, INC. | $33,627 | 26 | $0 (2020) |
| UCB, Inc. | $27,899 | 31 | $0 (2024) |
| Amgen Inc. | $20,438 | 31 | $0 (2024) |
| LEO Pharma AS | $13,922 | 22 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $34,126 | 94 | Eli Lilly and Company ($16,274) |
| 2023 | $38,265 | 98 | Sun Pharmaceutical Industries Inc. ($10,971) |
| 2022 | $66,514 | 110 | Incyte Corporation ($35,704) |
| 2021 | $26,525 | 37 | SUN PHARMACEUTICAL INDUSTRIES INC. ($9,740) |
| 2020 | $47,329 | 70 | Amgen Inc. ($8,855) |
| 2019 | $290,894 | 169 | Celgene Corporation ($130,491) |
| 2018 | $59,884 | 96 | Sun Pharmaceutical Industries Inc. ($14,960) |
| 2017 | $90,764 | 114 | Genentech USA, Inc. ($54,381) |
All Payment Transactions
788 individual payment records from CMS Open Payments — Page 1 of 32
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $18.25 | General |
| 12/17/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $5.66 | General |
| Category: Dermatology | ||||||
| 12/16/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $15.56 | General |
| Category: Inflammation | ||||||
| 12/13/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $11.64 | General |
| 12/09/2024 | Lilly USA, LLC | TALTZ (Drug), ZEPBOUND, EBGLYSS | Food and Beverage | In-kind items and services | $16.40 | General |
| Category: Immunology | ||||||
| 12/03/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $39.34 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/27/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $23.52 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $4.33 | General |
| Category: IMMUNOLOGY | ||||||
| 11/14/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $3.36 | General |
| Category: Dermatology | ||||||
| 11/13/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $16.89 | General |
| Category: Immunology | ||||||
| 11/08/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $12.30 | General |
| Category: Immunology | ||||||
| 11/06/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $23.27 | General |
| Category: Immunology | ||||||
| 11/05/2024 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $1,050.00 | General |
| 10/23/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $6.39 | General |
| Category: Immunology | ||||||
| 10/15/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $13,603.00 | Research |
| Study: A STUDY OF LY3972406 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | ||||||
| 10/03/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $33.16 | General |
| Category: Dermatology | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $2,557.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO ASSESS THE EFFICACY, SAFETY AND PHARMACOKINETICS OF LEBRIKIZUMAB COMPARED TO PLACEBO IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | ||||||
| 09/17/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $23.39 | General |
| Category: Immunology | ||||||
| 09/14/2024 | ABBVIE INC. | — | — | In-kind items and services | $143.48 | Research |
| Study: A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa | ||||||
| 09/14/2024 | ABBVIE INC. | — | — | In-kind items and services | $64.99 | Research |
| Study: A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa | ||||||
| 09/14/2024 | ABBVIE INC. | — | — | In-kind items and services | $45.06 | Research |
| Study: A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa | ||||||
| 09/14/2024 | ABBVIE INC. | — | — | In-kind items and services | $18.53 | Research |
| Study: A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa | ||||||
| 09/13/2024 | ABBVIE INC. | — | — | In-kind items and services | $245.37 | Research |
| Study: A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa | ||||||
| 09/13/2024 | ABBVIE INC. | — | — | In-kind items and services | $111.56 | Research |
| Study: A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa | ||||||
| 09/13/2024 | ABBVIE INC. | — | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, STUDY OF THE EFFICACY AND SAFETY Of APREMILAST (CC-10004), COMPARED TO PLACEBO, IN SUBJECTS WTIH MILD TO MODERATE PLAQUE PSORIASIS (CC-10004-PSOR-022) | Celgene Corporation | $126,000 | 1 |
| A STUDY OF LY3972406 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $13,603 | 1 |
| A 12 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WITH A LONG TERM EXTENSION PERIOD | Eli Lilly and Company | $13,477 | 1 |
| A Study of the Efficacy and Safety of Apremilast CC-10004 in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp STYLE | Amgen Inc. | $7,888 | 1 |
| CC-10004-SPSO-001 - A Phase 3, Multi-Center, Randomized, Place-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004 in subjects with Moderate to Sever Plaque Psoriasis of the Scap) | Celgene Corporation | $4,832 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | Eli Lilly and Company | $4,586 | 2 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3375880 IN ADULT SUBJECTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: THE ADMIRE STUDY | Eli Lilly and Company | $3,224 | 1 |
| A MULTIPLE-DOSE, RANDOMIZED, PLACEBO-CONTROLLED, STUDY OF LY3462817 IN PATIENTS WITH PSORIASIS | Eli Lilly and Company | $2,922 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO ASSESS THE EFFICACY, SAFETY AND PHARMACOKINETICS OF LEBRIKIZUMAB COMPARED TO PLACEBO IN PARTICIPANTS 6 MONTHS TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $2,557 | 1 |
| EADV 2020 STYLE 16wk PROs and QOL Poster | Amgen Inc. | $2,383 | 1 |
| A Phase 3, Multi-Center, Randomized, Place-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004 in subjects with Moderate to Sever Plaque Psoriasis of the Scap) (CC-10004-SPSO-001) | Celgene Corporation | $2,096 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,885 | 1 |
| CC-10004-PSOR-009 | Celgene Corporation | $1,776 | 1 |
| Efficacy, Safety, PK, Biologics Monotherapy Study in Pts. with Moderate to Severe AD | SANOFI US SERVICES INC. | $1,486 | 8 |
| TRALOKINUMAB VACCINE RESPONSE TIME | LEO Pharma AS | $1,465 | 7 |
| A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) | AbbVie Inc. | $1,314 | 8 |
| CC-10004-PSOR-008 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects with Moderate to Severe Plaque Psoriasis | Celgene Corporation | $1,082 | 1 |
| A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy | AbbVie Inc. | $1,057 | 6 |
| PROTOPIC APPLES | LEO Pharma AS | $1,000 | 2 |
| EADV 2020 STYLE 16wk PROs and QOL Abstract | Amgen Inc. | $992.40 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose Study of the Efficacy, Safety, Tolerability, and Pharmacodynamics of Subcutaneously-Administered REGN668 in Adult Patients With Extrinsic Mo | SANOFI-AVENTIS U.S. LLC | $875.79 | 1 |
| A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa | ABBVIE INC. | $684.99 | 9 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3041658 IN ADULTS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA | Eli Lilly and Company | $548.95 | 2 |
| DUPIXENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $421.88 | 1 |
| CC-10004-PSOR-008 | Celgene Corporation | $417.00 | 1 |
| Study of REGN668/SAR231893 in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis | SANOFI-AVENTIS U.S. LLC | $340.59 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $153.65 | 1 |
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | Eli Lilly and Company | $114.46 | 1 |
| A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) | AbbVie Inc. | $98.25 | 1 |
| M15-997 | AbbVie, Inc. | $24.24 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 627 | 1,373 | $228,075 | $103,643 |
| 2022 | 14 | 668 | 1,411 | $260,985 | $120,998 |
| 2021 | 12 | 433 | 737 | $151,268 | $76,411 |
| 2020 | 11 | 423 | 836 | $132,925 | $57,836 |
Total Patients
2,151
Total Services
4,357
Medicare Billing
$358,887
Procedure Codes
52
All Medicare Procedures & Services
52 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 17311 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | Office | 2023 | 33 | 44 | $52,800 | $23,108 | 43.8% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 75 | 155 | $42,165 | $21,431 | 50.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 122 | 213 | $39,870 | $21,141 | 53.0% |
| 17312 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | Office | 2023 | 13 | 17 | $11,135 | $6,323 | 56.8% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 82 | 116 | $13,920 | $5,571 | 40.0% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 33 | 43 | $7,525 | $4,004 | 53.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 31 | 31 | $7,750 | $3,943 | 50.9% |
| 11602 | Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 16 | 18 | $5,680 | $3,843 | 67.7% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 70 | 543 | $19,005 | $3,008 | 15.8% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 18 | 24 | $5,400 | $2,728 | 50.5% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 27 | 31 | $5,425 | $2,550 | 47.0% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2023 | 57 | 82 | $10,660 | $2,518 | 23.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 22 | 24 | $3,240 | $1,734 | 53.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 17 | 21 | $1,575 | $991.00 | 62.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 11 | 11 | $1,925 | $750.44 | 39.0% |
| 17311 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | Office | 2022 | 49 | 60 | $72,000 | $32,562 | 45.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 146 | 251 | $45,230 | $25,257 | 55.8% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2022 | 73 | 141 | $37,365 | $19,794 | 53.0% |
| 17312 | Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | Office | 2022 | 22 | 34 | $22,270 | $12,718 | 57.1% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 41 | 52 | $8,830 | $4,702 | 53.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 72 | 101 | $12,120 | $4,436 | 36.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 39 | 39 | $9,750 | $4,188 | 43.0% |
| 11602 | Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2022 | 15 | 19 | $6,315 | $3,777 | 59.8% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2022 | 64 | 101 | $13,130 | $3,191 | 24.3% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 64 | 524 | $18,340 | $2,892 | 15.8% |
About Dr. Howard Sofen, M.D
Dr. Howard Sofen, M.D is a Dermatology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/10/2005. The National Provider Identifier (NPI) number assigned to this provider is 1124026554.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Howard Sofen, M.D has received a total of $654,301 in payments from pharmaceutical and medical device companies, with $34,126 received in 2024. These payments were reported across 788 transactions from 43 companies. The most common payment nature is "" ($199,304).
As a Medicare-enrolled provider, Sofen has provided services to 2,151 Medicare beneficiaries, totaling 4,357 services with total Medicare billing of $358,887. Data is available for 4 years (2020–2023), covering 52 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Los Angeles, CA
- Active Since 07/10/2005
- Last Updated 03/18/2008
- Taxonomy Code 207N00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1124026554
Products in Payments
- Otezla (Drug) $151,807
- ILUMYA (Biological) $131,188
- Xolair (Biological) $60,898
- OPZELURA (Drug) $36,118
- QBREXZA (Drug) $33,627
- TALTZ (Drug) $20,400
- Bimzelx (Biological) $16,815
- Erivedge (Biological) $12,152
- ILUMYA (tildrakizumab-asmn) injection (Biological) $10,718
- Ilumya (Biological) $9,740
- Otezla (Biological) $7,902
- VTAMA (Drug) $7,208
- COSENTYX (Biological) $6,847
- Skyrizi (Biological) $5,336
- ODOMZO (sonidegib) capsules (Drug) $4,221
- TEZSPIRE (Biological) $3,275
- RINVOQ (Biological) $2,619
- LIBTAYO (Biological) $2,516
- Cimzia (Drug) $2,029
- DUPIXENT (Biological) $1,811
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Los Angeles
Christopher Ho, Md, MD
Dermatology — Payments: $929,207
Dermatology $929,207
Jennifer Hsiao, M.d, M.D
Dermatology — Payments: $400,325
Dermatology $400,325
Dr. Pearl Grimes, Md, MD
Dermatology — Payments: $358,500
Dermatology $358,500
Derek Jones, Md, MD
Dermatology — Payments: $316,086
Dermatology $316,086
Rebecca Fitzgerald, M.d, M.D
Dermatology — Payments: $281,818
Dermatology $281,818
Nada Elbuluk, Md, MD
Dermatology — Payments: $205,242
Dermatology $205,242